ASP Isotopes invests ~$10M in Opeongo, gets right of first offer on medical isotope supply

ASP Isotopes Inc.

Purchased 4,356,918 Series Seed-1 Preferred shares of Opeongo at $2.2952 per share (approx $10M investment).
Opeongo is a biotech developing ECM modulators for fibrosis, inflammation, and cancer; co-founded by David Baram and Irit Sagi.
ASPI secures right of first offer to supply medical isotopes for any Opeongo pharmaceutical product (supply agreement to be negotiated).
Related party: ASPI CEO Paul Mann designated as Series Seed-1 Director of Opeongo; CMO Todd Wider also a director.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ASP Isotopes Inc. entered into Series Seed-1 Preferred Stock Purchase Agreement with Opeongo, Inc. valued at $2.2952 per share (effective 2026-01-26).

Action: entry
Agreement: equity purchase
Counterparty: Opeongo, Inc.
Value: $2.2952 per share
Effective: 2026-01-26

Exact text from the filing

On January 26, 2026, ASP Isotopes Inc., a Delaware corporation (“ ASP Isotopes ” or the “ Company ”), entered into a Series Seed-1 Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) with Opeongo, Inc., a Delaware corporation (“ Opeongo ”), pursuant to which the Company agreed to purchase from Opeongo 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock, $0.0001 par value per share (the “ Series Seed-1 Preferred Stock ”), at a price of $2.2952 per share

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

ASP Isotopes Inc. filing history →

Source: SEC EDGAR

accession 0001477932-26-000555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.